NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 40 resultados LastUpdate Última actualización 17/01/2021 [14:19:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 2 nextPage   por página


NANOVESICLES DERIVED FROM ENHYDROBACTER BACTERIA, AND USE THEREOF

NºPublicación: EP3763829A1 13/01/2021

Solicitante:

MD HEALTHCARE INC [KR]

CN_111819294_A

Resumen de: EP3763829A1

The present invention relates to vesicles derived from Enhydrobacter bacteria and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, liver cirrhosis, and diabetes, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from Enhydrobacter bacteria according to the present invention can be effectively used for a method of diagnosing pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, liver cirrhosis, or diabetes, and for developing a composition for preventing, alleviating or treating the diseases.

traducir

REVERSE TRANSCRIPTASE AND USES THEREOF

NºPublicación: EP3763811A1 13/01/2021

Solicitante:

IRIGEN S L U [ES]

Resumen de: EP3763811A1

Reverse transcriptase and uses thereof. The present invention pertains to the fields of molecular and cellular biology. Particularly, it refers to a Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (RT) having increased thermal stability as compared to wild type M-MLV, characterized in that it comprises at least the mutation alanine to cysteine at the amino acid position 154 (A154C) and the mutation aspartic acid to cysteine at the amino acid position 224 (D224C), wherein a disulphide bond is formed between the thiol groups of the two cysteine amino acids at the amino acid positions 154 and 224.

traducir

HARRINGTONINES SALTS, IN PARTICULAR RETINOATES, THEIR PROCESS OF PREPARATION AND THEIR USES IN THE TREATMENT OF LEUKEMIAS, CANCERS, AUTOIMMUNE, SKIN, ALZHEIMER'S AND INFLAMMATORY BOWEL DISEASES AND VIRAL INFECTIONS, COMBINED WITH MYELOPOIESIS STIMULATING AGENTS

NºPublicación: EP3763715A1 13/01/2021

Solicitante:

ROBIN JEAN PIERRE [CH]

Resumen de: EP3763715A1

The present invention relates to salt of the following formula (I):Another object of the invention is a method for preventing or treating diseases selected among cancer, leukemias, lymphomas, myelodysplastic syndrome, autoimmune diseases, skin diseases, neurological diseases such as Alzheimer's disease, inflammatory bowel disease, such as Crohn's disease, and viral infections including papillomavirus comprising administering to a patient in need thereof an effective dose of the salt of formula (I) or a pharmaceutical composition comprising thereof.The present invention also relates to a method of preparation of the salt of formula (I).

traducir

METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS

NºPublicación: EP3761994A1 13/01/2021

Solicitante:

GLYCOMIMETICS INC [US]

KR_20200128025_A

Resumen de: WO2019173229A1

Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.

traducir

Methods and compositions for inhibition of dihydroorotate dehydrogenase

NºPublicación: AU2019288813A1 07/01/2021

Solicitante:

OHIO STATE INNOVATION FOUNDATION
HENDRIX COLLEGE

WO_2019246603_PA

Resumen de: AU2019288813A1

Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1'-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

traducir

METHODS OF TREATING CANCER IN PEDIATRIC PATIENTS

NºPublicación: US2021000845A1 07/01/2021

Solicitante:

ARIAD PHARMA INC [US]

KR_20200132899_A

Resumen de: US2021000845A1

Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.

traducir

KDM1 A inhibitors for the treatment of disease

NºPublicación: AU2019265022A1 07/01/2021

Solicitante:

IMAGO BIOSCIENCES INC

Resumen de: AU2019265022A1

The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1 A for the treatment or prevention of diseases. Methods of inhibition of KDM1 A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.

traducir

Amplification method

NºPublicación: AU2019284210A1 07/01/2021

Solicitante:

MONOQUANT PTY LTD

WO_2019237146_A1

Resumen de: AU2019284210A1

The present invention relates generally to an improved method of amplifying a nucleic acid region of interest and to primers for use therein. More particularly, the present invention is directed to an improved method of amplifying a nucleic acid region which has resulted from the recombination of two or more immunoglobulin or T cell receptor gene segments and primers for use therein. The method of the present invention is based on the determination that performing the amplification step using primers which exhibit a high Tm and/or using a high annealing temperature enables higher levels of sensitivity than has previously been achievable in the context of prior art methods of amplifying rearranged immunological or T cell receptor genes. Still further improvements in sensitivity are achievable where the subject primer hybridises to at least two N regions of the recombined gene. The provision of a highly sensitive yet simple means of detecting specific immunological and T cell receptor nucleic acid recombination events is useful in a range of applications including, but not limited to, the diagnosis and/or monitoring of clonal lymphoid cell populations or disease conditions which are characterised by specific V/D/J recombination events (such as detecting minimal residual disease in leukaemias) or the analysis or identification of immunological or T cell receptor gene regions of interest.

traducir

Amplification method and primers for use therein

NºPublicación: AU2019284211A1 07/01/2021

Solicitante:

MONOQUANT PTY LTD

WO_2019237146_A1

Resumen de: AU2019284211A1

The present invention relates generally to an improved method of amplifying a nucleic acid region of interest and to primers for use therein. More particularly, the present invention is directed to an improved method of amplifying a nucleic acid region which has resulted from the recombination of two or more immunoglobulin or T cell receptor gene segments and primers for use therein. The method of the present invention is based on the determination that performing the amplification step at an annealing temperature determined relative to the critical annealing temperature unique to a given reaction and/or using optimised primers enables higher levels of sensitivity than have previously been achievable in the context of prior art methods of amplifying rearranged immunological or T cell receptor genes. The method of the present invention is particularly useful where the subject recombination target comprises only one N region. The provision of a highly sensitive yet simple means of detecting specific immunological and T cell receptor nucleic acid recombination events is useful in a range of applications including, but not limited to, the diagnosis and/or monitoring of clonal lymphoid cell populations or disease conditions which are characterised by specific V/D/J recombination events (such as detecting minimal residual disease in leukaemias) or the analysis or identification of immunological or T cell receptor gene regions of interest.

traducir

Methods of use of CD24 for the prevention and treatment of leukemia relapse

NºPublicación: AU2019282530A1 07/01/2021

Solicitante:

ONCOIMMUNE INC
UNIVERSITY OF MARYLAND BALTIMORE

TW_202015753_A

Resumen de: AU2019282530A1

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

traducir

Engineered hematopoietic stem cells for the treatment of acute myeloid leukemia

NºPublicación: AU2019285044A1 07/01/2021

Solicitante:

UNIV LOMA LINDA
LOMA LINDA UNIV MEDICAL CENTER
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERISTY SCHOOL OF MEDICINE

WO_2019241479_PA

Resumen de: AU2019285044A1

In one aspect, engineered hematopoietic stem cells comprising a heterologous expression cassette are provided. In some embodiments, the expression cassette comprises a promoter operably linked to a polynucleotide that encodes a 1α-hydroxylase protein, wherein the 1α-hydroxylase protein is human cytochrome P450 family 27 subfamily B member 1 (CYP27B1).

traducir

Antibodies against LIF and dosage forms thereof

NºPublicación: AU2019269131A1 07/01/2021

Solicitante:

MEDIMMUNE LTD
FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL HEBRON
FUNDACIO PRIVADA INST CATALANA DE RECERCA I ESTUDIS AVANCATS

CA_3099406_A1

Resumen de: AU2019269131A1

Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer and effective doses of these antibodies.

traducir

CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY

NºPublicación: EP3760217A1 06/01/2021

Solicitante:

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT [DE]
UNIV BERLIN CHARITE [DE]

Resumen de: EP3760217A1

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners.

traducir

A CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO B-CELL MATURATION ANTIGEN, A RECOMBINANT EXPRESSION VECTOR AND A METHOD THEREOF

NºPublicación: US2020405758A1 31/12/2020

Solicitante:

MED MANOR ORGANICS P LTD [IN]

WO_2017130223_PA

Resumen de: US2020405758A1

A chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA), a recombinant expression vector and a method for the development of the genetically modified immune effector cells especially natural killer-92 cells (NK-92 cells) that target Multiple Myeloma (MM) and other hematological malignancies. The invention encompasses a single chain variable region (scFv) from BCMA specific antibody fused via transmembrane domain to intracellular signaling domain and two co-stimulatory molecules. Expression of CARs across the plasma membrane of immune effector cells such as natural killer cells (NK cells), NK-92 cells, T lymphocytes (T cells) and natural killer T cells (NKT cells) with exposed scFv interacting with the BCMA tumor target. The interaction initiates cascade of events through the intracellular stimulatory and signaling domains leading to the activation of immune effector cells followed by lysis of the tumor. The invention also includes methods of administering a genetically modified immune effector cells expressing a CAR that comprises a BCMA binding domain. FIG. 4 is the representative figure.

traducir

TROPHOBLAST GLYCOPROTEIN (5T4, TPBG) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

NºPublicación: US2020407461A1 31/12/2020

Solicitante:

CELLECTIS [FR]

ES_2777305_T3

Resumen de: US2020407461A1

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

traducir

N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS

NºPublicación: US2020407356A1 31/12/2020

Solicitante:

REDX PHARMA PLC [GB]

Resumen de: US2020407356A1

Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

traducir

HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA

NºPublicación: US2020405716A1 31/12/2020

Solicitante:

ACETYLON PHARMACEUTICALS INC [US]

Resumen de: US2020405716A1

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

traducir

ALK POLYPEPTIDES AND METHODS OF USE THEREOF

NºPublicación: US2020405834A1 31/12/2020

Solicitante:

VEDANTRA PHARMACEUTICALS INC [US]

CA_3012764_A1

Resumen de: US2020405834A1

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

traducir

NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER

NºPublicación: US2020408765A1 31/12/2020

Solicitante:

SANOFI SA [FR]

ES_2726754_T3

Resumen de: US2020408765A1

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

traducir

COMPOSITIONS, ASSAYS, AND METHODS FOR DIRECT MODULATION OF FATTY ACID METABOLISM

NºPublicación: US2020408767A1 31/12/2020

Solicitante:

DANA FARBER CANCER INST INC [US]

CA_3029622_A1

Resumen de: US2020408767A1

This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid β-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid β-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.

traducir

COMPOSITIONS COMPRISING A RETINOID X RECEPTOR (RXR) AGONIST, A RETINOIC ACID RECEPTOR (RAR) AGONIST, OR A DUAL RXR/RAR AGONIST

NºPublicación: WO2020263960A1 30/12/2020

Solicitante:

WAGNER CARL [US]
MARSHALL PAMELA [US]
JURUTKA PETER [US]

Resumen de: WO2020263960A1

The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.

traducir

HCK DEGRADERS AND USES THEREOF

NºPublicación: WO2020263935A1 30/12/2020

Solicitante:

DANA FARBER CANCER INST INC [US]
GRAY NATHANAEL S [US]
BUHRLAGE SARA JEAN [US]
TAN LI [CN]

Resumen de: WO2020263935A1

Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a kinase (e.g., HCK, BTK) to induce degradation of the kinase (e.g., HCK, BTK). Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., non-Hodgkin's lymphoma, Burkitt's lymphoma, Waldenstrom macroglobulinemia, MYD88-mutated Waldenstrom macroglobulinemia, activated B-cell diffuse large B-cell lymphoma, leukemia)), inflammatory disease, or other diseases associated with MYD88 mutations). Provided also are methods of inducing the degradation of a kinase (e.g., HCK, BTK) in a cell in a biological sample or subject by administering the bifunctional compound or composition described herein.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS

NºPublicación: WO2020262974A1 30/12/2020

Solicitante:

HANMI PHARM IND CO LTD [KR]

Resumen de: WO2020262974A1

Provided are: a pharmaceutical composition for treating acute myeloid leukemia (AML); and a method for treating acute myeloid leukemia using same. The pharmaceutical composition comprises a therapeutically effective combination of: an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof; and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

traducir

E3 LIGASE BINDERS AND USES THEREOF

NºPublicación: WO2020263832A1 30/12/2020

Solicitante:

DANA FARBER CANCER INST INC [US]

Resumen de: WO2020263832A1

Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein bind an E3 ubiquitin ligase (e.g., Cereblon) and induce degradation of a transcription factor (e.g., IKZF1, IKZF3). Also provided are pharmaceutical compositions comprising the compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers (e.g., carcinoma); leukemia, lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer, multiple myeloma, and acute myeloid leukemia (AML))). Further provided are methods of inducing the degradation of a transcription factor (e.g., IKZF1, IKZF3) by administering a compound or composition described herein to a subject and/or to a biological sample (e.g., cell or tissue).

traducir

DETECTION OF RELB ACTIVATION FOR PREDICTING A PROGNOSTIC IN B-CELL LYMPHOMA

Nº publicación: WO2020260453A1 30/12/2020

Solicitante:

UNIV DE PARIS [FR]
INST NAT SANTE RECH MED [FR]

Resumen de: WO2020260453A1

The invention relates to a method for predicting the prognosis of a patient suffering from a B-cell lymphoma, through the detection of the status of activation of the RelB protein, in a biological sample of said patient. The inventors indeed identified an associated gene expression signature in the biological sample. Some genes from said signature are over-expressed and other are under-expressed and allow detecting RelB activation and predicting a worse prognosis in B-cell lymphoma.

traducir

Página1 de 2 nextPage por página

punteroimgVolver